Patient education and monitoring recommendations for the use of glucagon-like peptide-1 receptor agonists

Journal of Family Practice

Volumn 58, Issue 9 SUPPL., 2009, Pages

  Haines, Stuart T ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; PIOGLITAZONE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; CASE REPORT; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LEG SWELLING; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MONITORING; MOTIVATION; NAUSEA; NEEDS ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; POSITIVE FEEDBACK; SELF CARE; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PATIENT EDUCATION AS TOPIC; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 70349118584     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self-management education. Diabetes Care. 2009;32(suppl 1):S87-S94.
2. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009;32(suppl 1):S13-S61.
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
4. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834-838.
5. Byetta [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2008.
6. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
7. Vilsboll T, Zdravkovic M, Le Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610. (Pubitemid 46871185)
8. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335-1342. (Pubitemid 38679980)
9. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915-1921. (Pubitemid 38989232)
10. Degn KB, Jubl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187-1194. (Pubitemid 38569002)
11. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
12. DeFronzo RA, Ratner RF, Han J, et al.. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
13. Linnebjerg H, Kothare PA, Skrivanek Z, et al. Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med. 2006;23:240-245.
14. Amylin Pharmaceuticals, Inc. Byetta - Meal-time dosing.www.byetta.com/ patient/byetta-dosing-faq.jsp?reqNavId=5.4. Accessed April 21, 2009.